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1.1 Cutaneous wound healing  
Skin is the largest organ of the human body that covers the whole organism. As part 
of the integumentary system, it provides a natural barrier to shield internal organs and 
tissues from various kinds of insults, such as ultraviolet light, chemical damage, and 
mechanical injury. Under physiological circumstances, the skin sustains an intrinsically 
self-renewal process during a lifetime. However, once the continuous structure of the 
skin is breached, a series of cell signalling cascades are triggered to prevent further 
damage, avoid potential infection, and rebuild new tissue. In classic view, cutaneous 
wound healing is divided into four overlapping but distinct stages- haemostasis, 
inflammation, proliferation, and tissue remodelling (Figure 1, Figure 2) [1, 2]. Each 
stage functions uniquely by certain types of cells and molecules that communicate the 
signals to orchestrate the spatio-temporal repair process. 
The hemostasis response is originally provoked by the destruction of blood vessels 
that expose adventitia, the extracellular matrix (ECM) layer that adheres to the outer 
side of vessel endothelium [3]. The unveiling of damaged ECM initiates the coagulation 
cascade. Activated and degranulated platelets recruit and aggregate in the wound bed, 
interacting with the ECM proteins such as vitronectin, fibronectin, and 
thrombospondin and finally forming a fibrin clot that stops haemorrhage and blocks 
the infectious agents [4]. This fibrin clot also provides a basic matrix scaffold to 
facilitate migration of cells that are involved in the early healing phase.  Platelets caged 
in the clot also release various kinds of cytokines and growth factors such as platelet 
derived growth factor (PDGF) and transforming growth factor β (TGF β) into the 
surrounding wound environment. These factors make up the primary trigger to attract 
neutrophils and monocytes to the injury site to launch the inflammatory response [5].  
In the inflammatory phase the first type of cells that infiltrate the injured site are 
neutrophils. They clear cell debris, phagocytose microorganisms and secret proteases 
to eliminate fragmented ECM, which facilitates the following phase of wound 
response, including cell migration and new ECM deposition [6].  Neutrophils also 
release various kinds of chemokines and growth factors such as PDGF and TGF β to 
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commandeer other inflammatory cells (such as monocytes), endothelial cells and 
fibroblasts into the injured site [6]. Generally, neutrophils are cleared up in the wound 
site by apoptosis or are phagocytosed by macrophages as soon as pathogens are 
eradicated from the injury site [7]. 
Following neutrophils, monocytes are the second inflammatory cell type that arrive at 
the injury site. These monocytes originate from the circulating system and 
differentiate into macrophages once they arrive at the wound site. The differentiated 
macrophages on one hand function immunologically by killing microbe intruders, 
clearing away crumbled matrix to smooth out the space for laying down granulation 
tissue in the next phase [8]. On the other hand, differentiated macrophages, 
accompanied by the skin resident macrophages release various cytokines, chemokines, 
enzymes and growth factors including interleukins 1 and 6 (IL-1 and IL-6), PDGF, 
vascular endothelial growth factor (VEGF), fibroblast growth factors (FGFs) 
superfamily, and TGF β, which subsequently facilitate tissue repair in the next 
proliferating phase [8-10]. 
The proliferation phase is predominated by angiogenesis, granulation tissue formation 
and re-epithelialization. Angiogenesis is critical for the healing process as the growing 
tissue at the wound site is lacking in nutrients and is under hypoxic conditions. Even 
though VEGF and FGF-2 are considered to be the common stimuli that trigger the 
neovascularization events,  various kinds of cytokines and growth factors including 
hepatocyte growth factor (HGF), connective tissue growth factor (CTGF), VEGF and 
TGF β, as well as hypoxia, are considered to be promoting factors furnishing the 
capillary budding process [11-13]. Endothelial cells from vessels near the wound site 
are activated and secrete enzymes to lyse the basal membrane, sprout outside the 
vessels and at last form a new network of capillaries in the growing tissue [14]. The 
neovascularized system can then transport more oxygen and nutrients to the 
developing tissue and promote immune cell infiltration into the wound site to 
accelerate the healing process [14].  
Fibroblasts are also recruited to the wound site by chemokines and growth factors 
(mainly PDGF and TGF β) released in the previous inflammatory phase. They produce 
new ECM proteins including collagen III, fibronectin, proteoglycans, and hyaluronic 
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acid to refill the defect site [15, 16]. The loosely connected ECM scaffold intermingled 
with fibroblasts, macrophages and sprouted capillaries is termed as “granulation 
tissue” with a kind of soft and pink tissue-like appearance. Granulation tissue is fragile 
and can easily be traumatized. Fibroblasts are later activated into myofibroblasts that 
are characterized by the increased expression of alpha smooth muscle actin (α-SMA) 
[17]. Myofibroblasts can generate contractile force through creating multiple 
pseudopods that attach to the surrounding ECM and then retract them. This kind of 
contractile force enables myofibroblasts to contract the wound, pulling wound edge 
together to minimize wound area [18].   
Re-epithelialization initiates when the wound bed is filled up with granulation tissue, 
as keratinocytes need available tissue to attach and move across [19]. Keratinocytes 
that locate at the wound edge and in the epithelial stem cells reservoir in hair follicle 
bulge and interfollicular epidermis are the main contributors to the re-epithelialization 
process [20, 21]. Besides, epithelial stem cells from sweat glands and dedifferentiated 
sebaceous duct cells have also been reported to contribute to regenerating the 
epithelium [22, 23]. These keratinocytes or differentiated epithelial cells crawl from 
the wound edges and migrate along the surface of the granulation tissue, progressing 
in a sheet until the denuded territory is completely recovered. Growth factors such as 
epithelial growth factors (EGF) and keratinocyte growth factors (KGF) secreted by 
epithelial and non-epithelial cells have also been reported to promote the 
proliferation and migration of keratinocytes in this process [24]. Lastly, the newly 
formed epithelium layer undergoes stratification and differentiation to re-establish 
the squamous epidermal architecture that re-establish an intact skin.   
In the remodelling phase granulation tissue is finally replaced by a mass of acellular 
and avascular matrix. The disorganized ECM produced during the proliferation phase 
is rearranged. In mature scar tissue, ECM fibres are aligned parallelly to each other, 
which is different from the basket-weave reticular pattern in normal skin tissue. ECM 
proteins produced in the former stage undergo certain changes that are controlled by 
matrix metalloproteinases (MMPs) and their inhibitors - tissue inhibitor of matrix 
metalloproteinases (TIMPs) [25]. Specifically, loosely structured collagen III 
transforms into more tense-resisted collagen I, in company with the declined content 
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of hyaluronan and the transition of glycosaminoglycans into more robust proteoglycan 
molecules [2, 26]. The remodelling phase may last for several weeks to years. During 
this phase, the newly formed tissue (normally a scar tissue) gradually gains increased 
strength and tensity but will never completely reach the level of the original uninjured 
tissue [27].  
 
Figure 1. Four stages of skin wound healing. (a) In the hemostasis phase, platelets aggregate in the wound site and 
form fibrin clot to support cell migration. (b) In the inflammation phase macrophages and neutrophils attracted by 
PDGF and TGF β arrive later to phagocytose cell debris and external materials. (c) In the proliferation phase, 
fibroblasts are differentiated into myofibroblasts and deposit ECM; keratinocytes migrate along the granulation 
tissue to close the wound; endothelial cells are activated for angiogenesis. (d) At last, in the remodelling phase, 
growth factors and enzymes such as TGF β, PDGF, MMPs and TIMPs negotiate to transfer the previous fragile ECM 




  I. Introduction 
5 
 
Figure 2. Timelines of wound healing processes. Hemostasis is triggered immediately after wounding to arrest 
bleeding. Inflammation begins within hours after wounding and may last for several days. The proliferation phase 
begins 5 to 14 days after wounding. In this phase, fibroblasts are attracted to the wound site; angiogenesis and re-
epithelialization also occur during this phase. The remodelling phase already begins during the proliferation phase 
and could last for weeks to years (modified from Zomer, 2018) [28].  
1.2 Pathological scarring and scarless healing 
After injury, the innate surveillance system is intrinsically set off to reconstruct the 
integrity of tissue. This process leads to two extremely opposite results: tissue 
regeneration that forms an exact replica of the original tissue that regains most of the 
organ functions and physiologic performance; or scar formation that loses most of the 
function and physiologic performance. Whereas during fetal stages of development, 
injured skin may completely regenerate the original tissue architecture, this 
regenerative power is replaced at perinatal/postnatal life with scar tissue formation.  
Moreover, any inabilities to activate, discontinue or dysregulate the wound healing 
phases can lead to a pathological and exuberant scar in adult skin. These scars are 
typically referred to as hypertrophic scars or keloids which are featured as overgrowth 
of scar tissue characterised by excessive production of ECM (Figure 3: bottom). Such 
pathological scars usually develop when the deep layers of skin are damaged, as 
superficial trauma to the skin in most cases does not lead to hypertrophic scars or 
keloids. The range and severity of excessive scarring has been divided into two main 
categories defined by Mancini and Peacock in the last century [29, 30]. According to 
their definitions, a hypertrophic scar appears as a rigid connective tissue that is 
elevated on the top of the skin but is restricted to the wound area, whereas a keloid 
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extends the fibrotic tissue mass beyond the wound site and invades the adjacent 
tissue [31].  The emergence of these two types of pathological scars can dramatically 
lower the quality of life and has psychological and physical effects caused by limited 
tissue/organ mobility, increased pain, and pruritus [32]. A hypertrophic scar is 
characterized as erythematous-based, pruritic fibrotic tissue that protrudes above the 
skin surface. The main cause of hypertrophic scars is surgical manipulations, with 40-
70 % surgical operations leaving a hypertrophic scar. Burns are also a major trigger for 
hypertrophic scars, with a significant high incidence rate (around 91 %) in postburn 
wounds [33, 34]. Anatomically, hypertrophic scars usually develop in skin areas under 
tension such as neck and presternum or near knees and ankles [35, 36]. Once 
developed, hypertrophic scars grow rapidly at the early stage (up to 6 months) and 
then enter the remodelling phase, and regress over a few years into flattened scars 
[37]. In contrast, keloids are trapped in the proliferation phase and fail to progress into 
the remodelling phase of wound healing [38]. Keloidal scars may not degenerate after 
years and continue to undergo fibrotic growth similar to a benign tumour. Various 
kinds of insults can trigger keloid formation, including thermal injuries, surgical 
wounds, vaccinations, insect bites, infections, and endocrine dysregulation [39, 40]. 
Keloids mostly appear at anatomical sites that are devoid of hair follicles, such as 
upper part of the back, shoulders, earlobes and presternal skin [41, 42]. There is also 
a genetic susceptibility to keloid formation. Dark-skinned populations are found to be 
more prone to gain keloids than light-skinned populations, with an incidence rate of 
6-16 % in African people [43]. 
The pathomechanisms of hypertrophic scar and keloid formation are not completely 
clarified yet. However, chronic inflammation and imbalance towards collagen 
synthesis over collagen degradation are thought to be the common paths of the 
pathogenesis. Some researchers take hypertrophic scars and keloids as an 
inflammatory dysregulation of the skin, in particular, dysregulation of the reticular 
dermis [40]. Pro-inflammatory cytokines including tumour necrosis factor-α (TNF- α), 
IL-1α, IL-1β, and IL-6 are increased in keloids, which promote chronic inflammation 
and invasive growth of scarring tissue into the surroundings [44].  
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TGF β signalling is a key pathway that is involved in the formation of  pathological scars 
at various stages such as fibroblast activation, ECM production and myofibroblast 
differentiation. Until now, at least 45 polypeptides have been discovered in the TGF β 
family, and the most representative members are TGF β1, TGF β2 and TGF β3 [45]. 
TGF β1 and TGF β2 are reported to have a pro-scarring effect and TGF β3 has an 
opposite anti-scarring effect. Robust expression of TGF β family ligands and their 
corresponding receptors have been detected in fibroblasts of hypertrophic scars after 
burn injury [46]. Increased mRNA expression of TGF β1 and TGF β2 are also found in 
fibroblasts from keloids, whereas TGF β3 expression is dramatically decreased [47, 48]. 
In addition, TGF β up-regulates the expression of PDGF and VEGF in keloid-derived 
fibroblasts, which also favours fibroblast proliferation and ECM production [49, 50]. 
Pro-proliferative M2-type macrophages that stimulate fibroblast proliferation and 
collagen deposition in the proliferation phase of wound healing, are also abundant in 
keloids [51]. Overactive fibroblasts result in abnormal collagen synthesis of 
pathological scars, with a 7-fold increase in hypertrophic scars and an up to 20-fold 
increase in keloids, compared to that of normal skin tissue [52]. Histological analysis 
reveals that the main ECM in hypertrophic scars component is collagen III, which is 
normally present in the superficial dermis. In addition, hypertrophic scars are rich in 
nodules and extensive large collagen filaments. In contrast, keloids consist of thick 
collagen I and collagen III bundles with overactivated fibroblasts [53, 54]. A more 
detailed study characterizing the ECM composition of hypertrophic scars and keloids 
by reverse transcription polymerase chain reaction (RT-PCR) revealed that the 
expression of collagen I was approximately 3 to 4 times higher in hypertrophic scars 
and keloids and expression of hyaluronic acid was approximately 3 to 4 times lower 
than those in fetal tissues [55].   
In contrast to the formation of pathological scars, many lower-form organisms in 
nature have developed regenerative abilities that act quickly to structurally repair 
wound tissues after injuries without scarring. Decades ago, scientists have noticed 
that an early fetal wound usually heals by regenerating and restoring the construction 
of the original skin tissue, rather than healing with a non-functional scar [56] (Figure 3 
middle left). Specifically, the fetal dermis can lay down matrix proteins the same way 
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as the uninjured tissue. Furthermore, a higher level of hyaluronic acid is found in fetal 
skin tissues, compared to its equivalents in adults, which also promotes the 
regenerative restoration of skin structure [57, 58]. Interestingly, skin appendages such 
as hair follicles and sebaceous glands are also recreated in the healing fetal tissue [59]. 
Scarless healing is evolutionarily conserved in foetuses. Fetal scarless healing is not 
only restricted to humans but occurs also in many other mammals such as mice, rats, 
pigs, and monkeys [60, 61]. There are many factors that regulate wound healing 
towards a regenerative response. Studies have revealed that there was a low level of 
inflammation during the fetal wound healing process, suggesting that the absence of 
inflammation promotes rapid and impeccable healing of wounds [62]. This notion was 
further confirmed by Whitby, who observed a healing process towards development 
of scar tissue after inducing inflammation in fetal wounds [63]. Despite the alterations 
at the cellular level, cytokines at the molecular level also vary in fetal wounds. There 
is a low amount of pro-fibrosis growth factors including TGF β1, TGF-β2 and PDGF, and 
a high amount of anti-fibrosis growth factors like TGF β3 in fetal wounds [64]. Lastly, 
the high content of morphogenetic factors that engage in tissue growth and 
morphogenesis also contribute to a qualitative healing in foetuses that end in 
regeneration rather than scarring [64].  
Not only the developmental stage plays a role in determining the healing 
consequences, but also the anatomic site. Scarless healing also exists in adult 
mammals. One example comes from the regenerative wound healing in oral mucosa. 
As compared to skin wounds, oral wounds often heal faster and result in a non-scar 
tissue that is almost identical to the original tissue (Figure 3 middle right) [65, 66]. 
Interestingly, oral cavity wound healing shares some characteristics with the fetal 
healing process that brings on a perfect healing. The gingival fibroblasts are able to 
contract the lattice matrix faster than their counterparts in dermis [67]; there is a 
prolonged release of TGF-β3 in oral wounds [68]; the saliva in the oral cavity provides 
a moisture environment and unique profiles of growth factors and cytokines, similar 
to the effect of the amniotic fluid in uterus that drives a qualitative healing process 
[69]. Moreover, investigations showed that there is less infiltration of macrophages, 
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neutrophils, and T cells in the oral wound, due to a low number of cytokines such as 
IL-6 and IL-8 that hamper the inflammatory reaction [70, 71]. 
 
Figure 3. Schematic illustration of the structure of normal skin, two types of scarless healing and two types of 
pathological scars. Wound area is separated from the adjacent tissue by the dashed line. For scarless healing, fetal 
wound and oral wound share a debilitated inflammation response and similar skin structure as normal skin, 
demonstrated by the few macrophages and neutrophils in the wound bed without newly deposited ECM. In oral 
cavity, the humid environment also promotes the wound to heal scarlessly. For the two types of pathological scars, 
hypertrophic scar and keloid also share some characteristics, such as a high number of myofibroblasts, 
strengthened inflammation response and massive accumulated ECM. But in hypertrophic scar thin collagen fibres 
are aligned parallelly and the scar is restricted in the wound site. Whereas in keloid the scar tissue extends beyond 
the injury area and bulge above the skin, with disorganized ECM deposition and aggressive angiogenesis (Image is 
reproduced from Karppinen, 2019, with permission from F1000 Research) [44].  
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In the animal kingdom there are also cases of adult mammalian skin regeneration. For 
example, African spiny mice (genus Acomys), with outstanding repair and 
regeneration properties, represents a new model to study the evolutionary 
mechanisms that led to the loss of mammalian regeneration, and its replacement with 
scar tissue. On one hand, the relatively weak structure of the integumentary system 
of spiny mice makes it fragile and easy to break, which facilitates their escape from 
predators. On the other hand, the weak structured skin can quickly contract the 
wounds and regenerate the tissue (Figure 4) [72]. Notably, Acomys can fully 
regenerate the traumatized tissue after punch wounding in the ear, with de novo 
formation of hair follicles, sebaceous glands, cartilage, and adipose tissue [72, 73].  
Until now, most studies still focus on the conventional murine model, far less research 
has been given to the new Acomys model organism, and further investigation is 
needed to uncover the mystery of their postnatal regenerative capacity.  
Figure 4. African spiny mouse displays quick healing after injury. (a) One species of African spiny mouse- Acomys 
kempi. (b) Scab formation at post-injury day3 of full- thickness wounding. (c) Wounding area is covered with newly 
formed spiny hairs at post-injury day 30 (Image is reproduced from Seifert, 2012, with permission from Springer 
Nature, license number: 4794160601934) [72]. 
1.3 Introduction of fascia  
Fibroblasts are key players that not only produce and organize ECM in tissue but also 
interact with other cell types to orchestrate the dynamic wound healing process. With 
the various roles they play in a diversity of biological activities, fibroblasts are 
considered to be a heterogenous population consisting of distinct cell types. By 
conducting cell transplantation and lineage tracing experiments in mice, scientists 
have categorized fibroblast populations into two main classes on the basis of their 
surface expression and function, with papillary dermal fibroblasts expressing 
CD26+Sca1- in the upper dermis responsible for arrector pili and hair follicle formation, 
and reticular fibroblasts expressing Dlk1+Sca1- in the lower dermis accountable for 
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production of fibrillar ECM. When it comes to injury, the upper fibroblasts are 
recruited only for re-epithelialization, whereas the lower lineage cells are the 
contributors to the initial repair after wounding [75].  In 2015, Rinkevich et.al. 
identified a unique fibroblast lineage that is responsible for scar formation, namely 
Engrailed-1 positive fibroblast (EPF), as this fibroblast population is positive for the 
homeobox transcription factor Engrailed-1 during embryonic stages. By applying flow 
cytometry and surface marker screening panel, they determined CD26/ dipeptidyl 
peptidase-4 (DPP4) as the surface marker of EPFs. When inhibiting the CD26 positive 
cells with small molecular inhibitor, the wound healing process is delayed but it heals 
with almost no scar [76].   
A recent scientific study has uncovered fascia as a major source of scar formation in 
deep wounds [77]. But what is fascia? According to the definition from the Fascia 
Nomenclature Committee (2014), “The fascial system consists of the three-
dimensional continuum of soft, collagen containing, loose and dense fibrous 
connective tissues that permeate the body. It incorporates elements such as adipose 
tissue, adventitia and neurovascular sheaths, aponeuroses, deep and superficial 
fasciae, epineurium, joint capsules, ligaments, membranes, meninges, myofascial 
expansions, periosteum, retinacula, septa, tendons, visceral fasciae, and all the 
intramuscular and intermuscular connective tissues including endo-/peri-
/epimysium.  The fascial system interpenetrates and surrounds all organs, muscles, 
bones and nerve fibres, endowing the body with a functional structure, and providing 
an environment that enables all body systems to operate in an integrated manner.” 
[78] To be simplified, fascia is a sheet of connective tissue network that wraps the 
entire body, with fibroblasts, blood vessels, lymphatic tubes, adipose tissues, bones, 
cartilages, muscles, immune cells, and nerve systems integrated inside [78]. Collagen 
I and collagen III are the major ECM proteins that make up the supportive structure of 
fascia [79]. Besides, fascia tissue is also rich in hyaluronic acid that maintain the fluidic 
configuration and viscoelastic property of the tissue [80]. Among the various cell types 
resident in fascia, fibroblasts play a significant role in performing the fundamental 
functions of fascia such as tension transmission and tension resistance [81]. 
Fibroblasts can quickly flatten and spread out when fascia layer is extended by an 
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external force. This kind of morphological alteration on one hand assists fibroblasts to 
adapt themselves to the surroundings, on the other hand restrains the stress delivered 
to the deeper layers of the tissue [82]. In addition, fibroblasts are able to control and 
modulate ECM proteins to sustain the activity and integrity of fascia [83]. By secreting 
MMPs and TIMPs, the ECM synthesis and degradation in fascia are maintained in 
balance by fibroblasts [25].  
Fascia tissue is important for our body to function properly and is firmly related to our 
general health. The motion ability of our body is mediated through fascia by allowing 
muscles to slide smoothly. Fascia can sense the mechanical stress from the external 
environment and transmit the force to intra- and extra-muscular tissues [84]. Fascia is 
not just a protective layer that holds the body together, it is also linked to many 
diseases occurring in the body. Pathological fascia containing numerous 
myofibroblasts can lead to clinical symptoms like Dupuytren’s disease, Ledderhose’s 
disease and frozen shoulder, due to the great contractile force produced inside [85-
87]. Abundant nerve bundles distributed in fascia also relate to the pain sensation in 
patients. Relaxing fascial structures can relieve pain and increase mobility and muscle 
strength in patients diagnosed with patellar tendinopathy, chronic ankle sprain sequel 
and subacute whiplash disorder [88-90]. Table 1 gives a comprehensive view of the 
diseases caused by fascial dysfunctions [91].  
Table 1. Various of diseases caused by dysfunctions of fascia  
Table 1 is reproduced from Klingler, 2014 with permission from Springer Nature, license number: 
4794180639079 [91].  
  I. Introduction 
13 
 
In the wound healing field, many studies have previously focused on the function of 
fascia healing in abdominal wound repair. Failures in fascia healing after surgical 
celiotomy can be diagnosed only when hernias are identified, which not only cause 
sufferings for patients but also bring on huge economic loss in medical treatments [92]. 
It has been reported that fascia healing is important for successful abdominal wall 
restoration. The authors applied two different injury models to damage dermis and 
fascia, respectively, and found that fascia layer healed faster than dermis, with 
elevated fibroblast cellularity and collagen deposition, which finally resulted in fascial 
fibrosis [93]. In vitro cell culture experiments showed that, compared to their dermal 
counterparts, fascia fibroblasts exhibited superior cell proliferation ability and greater 
collagen compaction property, a distinguished phenotype that speeds up acute wound 
repair [94]. Surgeons also noticed that in clinical cases the standard subcutaneous 
suture method that stitches dermis and epidermis together could result in ischemia 
and multiply the chance to develop a hypertrophic scar. But this risk can be decreased 
when sutures were placed separately in deep fascia and superficial fascia to reduce 
tension force generated by fascia (Figure 5) [95, 96]. 
Figure 5. Standard subcutaneous suture (a) and fascia tension-reduced suture (b) (modified from Ogawa, 2011) 
[95].  
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Earlier studies were interested in defective fascia sliding that was affected by scarring 
and fibrosis. However, new findings linked fascia to wound healing and scar formation 
[77]. By transplanting murine fascia tissue and dermal tissue into immune-deficient 
mice separately, researchers found that fascia was the main contributor of scar 
formation in skin, rather than the classical view that regarded dermal fibroblast as the 
primary repair cells of wound healing. Further labelling of fascia tissue showed that 
fascia served as a mobile tissue that rapidly shifted to the defect area to fill the vacancy, 
alongside with the immune cells, vessels, lymphatic vessels, and nerves in the fascia 
tissue [77]. This new scientific discovery may give insights into further understanding 
of scar formation and wound healing, providing guidance to medical intervention for 
scarless repair. 
Even though mouse (Mus musculus) is the most often used species in animal models 
to mimic the human wound healing and scar formation, there are anatomic 
differences between the construction of human skin and murine skin (Figure 6). Both 
human skin and murine skin share a three-layer structure - epidermis, dermis and the 
subcutis. However, human skin is much thicker and is tightly attached to the 
underlying tissues. Murine skin is relatively thin and loose, with a weaker adherence 
to the tissue beneath it [97, 98]. In addition, mouse back skin has a subcutaneous 
muscle layer under the hypodermis, anatomically named as panniculus carnosus 
muscle, which is unique to murine skin but minimally present or completely absent in 
human skin. This special muscle layer extends contractile force to skin and allows 
wound closure to occur more rapidly in murine wounds than in human wounds. In 
contrast, in humans wound closure is largely completed by granulation tissue 
formation and re-epithelialization [99, 100]. Interestingly, fascia location and 
distribution also differ across human and murine skin. In mouse skin fascia tissue is a 
separate layer situated between panniculus carnosus and the skeleton muscle and 
comprised of several layers of connective tissue with fibroblasts, immune cells, nerve 
bundles, vessels and lymphatic vessels spread inside. In human skin there are two 
layers of fascia tissues, namely superficial fascia and deep fascia respectively. 
Superficial fascia is beneath the first fat layer and deep fascia is located between the 
second fat layer and the underlying muscle tissue (Figure 6).  
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Figure 6. Architecture of human skin and murine skin. Human skin is much thicker than murine skin. In human skin, 
there are two layers of fascia- superficial fascia and deep fascia; whereas in murine skin there is only one fascia 
layer that is located between the panniculus carnosus and skeleton muscle (image is reproduced and modified 
from Zomer, 2018, with permission from Elsevier, license number: 4794160601934) [28]. 
1.4 Drug repositioning and screening strategies  
Drug development is a high-priced, long-term, laborious, and complex process. 
Usually, it takes more than 10 years to develop a single effective drug, from biomarker 
identification and validation to modification and optimization, and progress to clinical 
trials before finally entering the market [101]. Conventional drug discovery undergoes 
five phases including target identification, preclinical research, safety evaluation, 
clinical trials, Food and Drug Administration (FDA) review and security risk assessment 
from FDA after marketing (Figure 7) [102, 103]. The fact that putting a new drug into 
market takes long development times and demands numerous costs with high 
attrition rates leads to more attention to drug repositioning in pharmaceutical 
industry. The aim of drug repositioning is to find new therapeutic effects of approved 
drugs that have initially been out of scope for the new treatment purpose. Compared 
to the conventional drug discovery strategy, drug repositioning is more efficient, less 
costly and with higher success rates. It usually goes through four stages including 
target molecular discovery, chemical acquisition, clinical research, and FDA 
monitoring after marketing (Figure 7). The timeline of discovering a “new” drug for 
drug repositioning decreases to 8 years on average [104]. 
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Figure 7. Schematic illustration of traditional drug discovery process (a) and drug-repositioning process (b) (image 
is reproduced from Ashburn, 2004, with permission from Springer Nature, license number: 4794171030385) [104]. 
ADMET, absorption, distribution, metabolism, excretion, and toxicity; EMEA, European Medicines Agency; FDA, 
Food and Drug Administration; IP, intellectual property; MHLW, Ministry of Health, Labour and Welfare. 
Phenotypic screening is a classical strategy to repurpose existing approved drugs for 
new treatments in diseases. Phenotypic screening is based on the unbiased 
phenotypic measurements in biological contexts, such as cells, tissues, or animal 
models, with no concerns about the correlation between chemicals or molecular 
targets and the expected therapeutic effect.  With known mechanism of action (MOA) 
and available clinical safety data of the old drugs, it takes less time and efforts to 
translate the alternated phenotypes into new therapeutic targets [105]. It is reported 
that between 1999 and 2008, 28 first-in-class drugs approved by FDA were identified 
and developed through phenotypic screening [106]. Many drugs including the first 
anti-HIV drug and the first anti-tuberculosis drug were hits upon by phenotypic 
screening [107, 108].  
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II. Materials and methods 
2.1 Mouse lines  
En1cre; R26mTmG, En1cre; R26mCherry, C57BL/6J were purchased from Charles River or 
Jackson laboratories or generated in Research Animal Facility at the Stanford 
University as previously described [76]. The Engrailed-1 (En1) gene is expressed in a 
small number of cells during embryogenetic stage. When the En1cre mouse is crossed 
with R26mTmG, Cre-Lox recombination will allow En1 positive cells to be green in the 
cell membrane and En1 negative cells to be red in cell membrane.  When the En1cre 
mouse is crossed with R26mCherry, Cre-Lox recombination will allow En1 positive cells 
to be mCherry in the cell nucleus and En1 negative cells express no fluorochrome.  
Animals were housed in the Animal Facility at Helmholtz Zentrum München at 
constant temperature and humidity with a 12-hour light cycle. Food and water were 
provided ad libitum. All the tissues used in this thesis were collected as organ 
withdrawal after sacrificing the animals. All the experiments conducted in this thesis 
were done ex vivo. 
2.2 Ex vivo skin explant assay   
Post born Day 0 (P0) neonates of C57BL/6J wild type mice were first sacrificed by 
decapitation.  Then dorsal back skin was isolated to make 2 mm full thickness biopsies 
(ø 2mm, Stiefel) that included the epidermis, dermis, and deep subcutaneous fascia 
layers. The whole skin tissue explant system is termed as scar-in-a-dish (SCAD) assay 
(Patent Application no. PLA17A13). The SCAD tissue was maintained in DMEM/F12 
cell culture medium (Life Technologies) supplemented with 10 % FBS (Life 
Technologies), 1 % non-essential amino acid (Thermo Fisher), 1 % Glutamax (Thermo 
Fisher), 1 % penicillin and streptomycin (Thermo Fisher) in a 37 °C incubator supplied 
with 95 % O2 and 5 % CO2. Medium was changed every other day until day 5 when 
SCADs were collected and fixed for histology analysis. Of note, the excised skin was 
submerged dermis-side up in culture media, which confined the scar-prone fibroblasts 
to the explant and discouraged their adherence to the tissue culture plate.  
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2.3 Prestwick chemical library® (PCL) and automatic screening of chemicals 
The Prestwick library contains 1280 approved small molecules approved by FDA, 
European Medicines Agency (EMA)  or other agencies that covers a range of major 
anatomical therapeutic classes including central nervous system (19 %), 
cardiovascular system (11 %), metabolism (24 %) and infectious diseases (16 %). The 
purity of the compounds was > 90 % as reported by the provider of the compounds. 
The PCL provides an additional advantage as all chemicals are of stable 
physicochemical properties, show a high range of chemical diversity, and are with 
known bioavailability and safety data in humans. All this information helps to reduce 
the probability of screening low-quality hits and save the costs of preliminary 
screening process. More details about drug therapeutic category and drug targets are 
shown in Figure 8.   
 
 
Figure 8. Anatomical Therapeutic Chemical (ATC) classification and target distribution of PCL [109] (Reproduce 
permission obtained by Prestwich Chemical). 
In order to accommodate to medium scale screening approach, we adapted the SCAD 
explant system into 96-well plate (Falcon) formats, with each well containing one 
biopsy. The novel 96-well SCAD pipeline was then combined with the 1280 approved 
small molecules from the Prestwick chemical library. Plate and liquid handling were 
performed using a high-throughput screening platform system composed of a Sciclone 
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G3 Liquid Handler from PerkinElmer (Waltham, MA, USA). On Day 0 tissues were 
treated either with the respective compound (1 mM stock solution) dissolved in 100 % 
dimethyl sulfoxide (DMSO, Carl Roth) or DMSO alone; 0.5 µl of compounds/ DMSO 
were transferred with a 96-array head to 200 µl DMEM/F12 medium per well to keep 
the final DMSO concentrations at 2.5 µM. Tissues were then incubated (37 °C; 5 % CO2) 
for 72 h prior to a second round of compound treatment, exchanging the cell culture 
medium per well and transferring 2.5 µM of compounds/ DMSO into the fresh 
medium. After an incubation time of another 48 h (37 °C; 5 % CO2) the tissues were 
harvested and fixed for histological processing and imaging. 
2.4 Ex vivo fascia and dermis culture— suspension assay 
The connective tissue between the panniculus carnosus and the skeleton muscle of 
mouse dorsal skin is part of the fascia tissue that wraps the entire body. Aiming to 
investigate the roles of dermis and fascia played in scarring, we established an ex vivo 
suspension assay. Firstly, P4 to P6 C57BL/6J neonates were sacrificed by decapitation. 
Then dorsal back skin with the fascia layer was carefully dissected to make 4 mm full 
thickness biopsies. A stereo brightfield microscope was used to separate fascia tissue 
from the back skin. After removing fascia tissue, the panniculus carnosus was exposed 
and removed to retain only dermis part. Both dermis and fascia samples were then 
maintained in 600 µl DMEM/F12 medium (Life Technologies) supplemented with 10 % 
FBS (Life Technologies), 1 % non-essential amino acid (Thermo Fisher), 1 % Glutamax 
(Thermo Fisher) and 1 % penicillin and streptomycin (Thermo Fisher)  in a 24-well plate 
(Falcon) and cultured in a 37 °C incubator. After 6 days’ culture the tissues were 
harvested and fixed for histological processing and imaging. 
2.5 Ex vivo fascia three-dimensional (3D) culture— fascia invasion assay 
To create a 3D environment that mimics the physiological environments in vivo, we 
established a fascia Matrigel (Corning) system. Fascia tissues were isolated by the 
same approach as described in chapter 2.4, but with P4 to P6 neonates of En1cre; 
R26mTmG mouse lines. Cre positive neonates from this double transgenic mouse line 
were detected by green fluorescent signal in dorsal skin with a Leica M205 FA stereo 
microscope. Matrigel was prepared by diluting the stock aliquots with plain 
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DMEM/F12 medium to a concentration of 6 mg/ml. Then 150 µl prepared gel was 
added in the center of a 35 mm cell culture dish (Ibidi). Four millimetre biopsies were 
made from the dorsal skin and fascia tissues were then isolated from the dorsal skin 
tissues. Isolated fascia tissues were then embedded into the gel and were allowed to 
be solidified for one hour at 37 °C. Then the tissue-gel system was maintained in 
DMEM/F12 medium (Life Technologies) supplemented with 10 % FBS (Life 
Technologies), 1 % non-essential amino acid (Thermo Fisher), 1 % Glutamax (Thermo 
Fisher), 1 % penicillin and streptomycin (Thermo Fisher) in a 37 °C incubator supplied 
with 95 % O2 and 5 % CO2. Medium was changed every other day until day 4 when 
tissues were collected and fixed. For fixation with Matrigel system, tissues were fixed 
in 2 % paraformaldehyde (VWR) with 0.1 % glutaraldehyde (Sigma) for 1 hour and then 
washed three times with phosphate buffered saline (PBS, Life Technologies) and 
stored in PBS at 4 °C. 
2.6 Invasion index and contraction index measurement 
Fascia tissues were recorded everyday by a brightfield microscope to check the 
invasion and contraction state of the tissues. The invasion index was calculated with 
the following formula: 
                                        Invasion index= (SD4 - SD0)/SD0 
SD4 and SD0 represent tissue size (including the migrated area) on Day 4 and Day 0, 
respectively. The contraction index was calculated with the following formula: 
Contraction index= (TD0 – TD4)/TD0 
TD4 and TD0 represent original tissue size (excluding the migrated area) on Day 4 and 
Day 0 respectively. 
2.7 Histology  
Except otherwise stated, all the samples were fixed overnight in 2 % 
paraformaldehyde (VWR) in PBS at 4 °C and washed three times with PBS. Samples 
were then embedded in optimal cutting temperature compound (OCT, Sakura Finetek) 
and snap frozen on dry ice. 6 µm frozen sections were made by a cryostat (Cryostar 
NX70, Thermo fisher) and frozen section slides were stored at -20 °C. Masson’s 
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trichrome staining was applied using a trichrome stain kit (Sigma-Aldrich) according to 
the manufacturer's instructions. Briefly, frozen section slides were immersed in 
preheated Bouin’s Solution at 56 °C for 15 minutes, then washed in running tap water 
to remove excess Bouin’s reagent from the sections. Afterwards staining was 
performed in working Weigert’s Iron Haematoxylin solution (prepared by mixing equal 
volume of Solution A and Solution B purchased from Sigma) for 5 minutes followed by 
washing in running tap water for another 5 minutes.  Afterwards, slides were rinsed 
in deionized water and stained in Biebrich Scarlet-Acid Fuchsinn for 5 minutes. After 
rinsing in deionized water again, slides were placed in working 
phosphotungstic/phosphomolybdic acid solution for 5 minutes. Working 
phosphotungstic/phosphomolybdic acid solution was prepared by mixing 
phosphotungstic, phosphomolybdic acid and deionized water in a 1:1:2 ratio. 
Counterstaining was performed in aniline blue solution for 10 minutes and then in 1 % 
acetic acid for 2 minutes. Finally, slides were rinsed in Histol Clear (Carl Roth) and 
mounted with permanent mounting medium (Carl Roth). Images were recorded by a 
ZEISS AxioImager. Z2m (Carl Zeiss) with brightfield channel. In Masson’s trichrome 
staining, muscle fibres and keratin are stained as red colour, collagen is stained as blue, 
cytoplasm is stained as light red and cell nuclei is stained as black. 
2.8 Cell culture 
Human dermal fibroblast cell line FF95 [110] was used to test the morphological 
changes and ECM deposition of different treatments. Forty thousand cells per well 
were seeded in an 8-well removable chamber slide (Ibidi) coated with 2 % gelatin 
(Sigma). Cells were maintained in DMEM medium supplemented with 10 % FBS (Life 
Technologies), 1 % non-essential amino acid (Thermo Fisher), 1 % Glutamax (Thermo 
Fisher), 1 % penicillin and streptomycin (Thermo Fisher) in a 37 °C incubator supplied 
with 95 % O2 and 5 % CO2. Culture medium was changed every other day. On day 4 
cells were harvested, fixed in 4 % paraformaldehyde (VWR) and washed with PBS (Life 
Technologies) for three times. Fixed cells can be stored at 4 °C or be processed for 
immunocytochemistry. 




Frozen sections were equilibrated at room temperature for 10 minutes and then post-
fixed for 5 min in -20 °C acetone. Sections were then rinsed three times with PBST (PBS 
supplemented with 0.5 % Tween-20 (Sigma)) and blocked with 10 % donkey serum or 
goat serum (the serum used is of the same species as the secondary antibody, Sigma). 
After blocking, primary antibodies diluted in PBST were added to the slide and 
incubated overnight at 4 °C or two hours at room temperature. Sections were then 
rinsed three times again with PBST and incubated with secondary antibodies for one 
hour at room temperature. At last, sections were washed three times with PBST to 
remove the excessive antibodies and mounted with fluorescent mounting medium 
containing 4,6-diamidino-2-phenylindole (DAPI, Thermo Fisher Scientific). Imaging 
was performed by an inverted Zeiss LSM 710 confocal microscope. Primary and 
secondary antibodies used are listed in Table 2.  
Table 2. Antibodies used in immunohistochemistry 
Antibody Species   Dilution Company Catalog No. 
Collagen I Rabbit 1: 200 Tebu-Bio 600-401-103 
Fibronectin Rabbit 1: 200 Abcam ab23750 
CD26 Goat 1: 250  R&D Systems AF954 
CK14 Rabbit 1: 1000 Abcam ab181595 
Donkey anti rabbit AF647 Donkey 1: 500 Life Technologies A-31573 
Donkey anti goat AF647 Donkey 1: 500 Life Technologies A-21447 
 
2.10 Immunocytochemistry 
The staining process of immunohistochemistry was the same as described in 
Immunohistochemistry (Chapter 2.9). Samples were imaged by an inverted Zeiss LSM 
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Table 3. Antibodies used in immunocytochemistry 
Antibody Species  Dilution Company Catalog No. 
AF 647- Phalloidin  - 1: 500 LIFE Technologies A22287 
Tubulin Rat 1:1000 Abcam ab6160 
Collagen I Rabbit 1:400 Tebu-Bio 600-401-103 
Collagen III Rabbit 1:400 Abcam ab7778 
Fibronectin Rabbit 1:400 Abcam ab23750 
Donkey anti rabbit AF647 Donkey 1: 1000 Life Technologies A-31573 
Goat anti rat AF 568 Goat 1: 1000 Life Technologies A-11077 
 
2.11 3D staining and whole mount imaging 
In order to characterize the properties of fascia samples cultured in Matrigel, we fixed 
the whole gel (with fascia tissue embedded inside) and conducted 3D staining. 
Samples were immersed overnight in PBSGT (1x PBS implemented with 0.2 % gelatin 
(Sigma), 0.5 % Triton X-100 (Sigma) and 0.01 % thimerosal (Sigma)) at room 
temperature and incubated with primary antibodies diluted in PBSGT for three days 
at room temperature. The tissues were then washed three times with PBSGT for at 
least 30 min each time and incubated with secondary antibodies diluted in PBSGT for 
one day. Finally, tissues were rinsed three times with PBSGT and stored in PBS at 4 °C 
until imaging. 3D whole mount imaging was conducted with a Leica SP8 multi-photon 
microscope. Primary and secondary antibodies applied in 3D staining were listed in 
Table 4.  
Table 4. Antibodies used in 3D staining 
Antibody Species  Dilution Company Catalog No. 
αSMA Goat 1:500 Abcam ab21027 
FAK Rabbit 1:500 Elabscience E-AB-33910 
Ki 67 Rabbit 1:350 Abcam ab16667 
Cleaved Caspase-3  Rabbit 1:400 Cell signalling 9661S 
Gli1 Rabbit 1:400 Abcam ab49314 
Donkey anti rabbit AF647 Donkey 1: 1000 Life Technologies A-31573 
Donkey anti goat AF647 Donkey 1: 1000 Life Technologies A-21447 
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2.12 Live imaging 
Fascia tissue cultured in Matrigel was fixed in 2 % low-melting agarose (Biozym) and 
left at room temperature to be solidified. DMEM/F12 medium without phenol red was 
then added to keep the tissues alive during imaging. Four-dimension (4D) time-lapse 
images were performed by a Zeiss AxioObserver Z1 microscope for tissues obtained 
from En1cre; R26mCherry mouse line or a Leica SP8 multi-photon microscope for tissues 
obtained from En1cre; R26mTmG mouse line. Samples were placed in a qualified 
incubator with heating and gas control (Ibidi). The incubator temperature was 
adjusted to 35 °C and was supported with 5 % CO2 during imaging. Brightfield and 
mCherry signals were recorded for tissues from En1cre; R26mCherry; green fluorescent 
protein (GFP) and tdTomato signals were recorded for tissues from En1cre; R26mTmG. 
2.13 Cell tracking 
4D time-lapsed imaging was subjected to maximum intensity projection in Imaris 9.3.1 
(Bitplane) or Zeiss (Blue edition) software. The projected data sets were proceeded to 
cell migration and cell-tracking analysis using the automatic tracking function of Imaris 
9.3.1. Variables, such as spot diameter and threshold were adjusted to suit the nature 
of the data and the samples. For the fourth dimension of the tracks, colour ramp was 
applied to the individual tracks as a function of time (blue, first time point of the track; 
orange, last time point of the track). 
2.14 Data analysis 
3D images and time series videos were processed with Imaris 9.3.1 (Bitplane). 
Brightness and contrast were modified to exclude false positive signals and to obtain 
better visibility. Fractal analysis was conducted using the ImageJ plug in ‘FracLac’29 
(FracLac 2015Sep090313a9390) [111]. Fractal dimension (DF) values and  Lacunarity 
(Lac) values were calculated using the box counting approach (slipping and tighten 
grids were set at default sample sizes, threshold of minimum pixel density was set as 
0.40) [112].  
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2.15 Statistics and reproducibility 
Statistical analysis was performed using GraphPad Prism software (Version 7.0, 
GraphPad). Until otherwise stated, all results were repeated with at least three 
independent experiments or three biological samples with consistent results. Cell 
tracking in Figure 15, Figure 16, and Figure 17 were derived with two single movies. 
3D staining was performed on two samples and images were recorded at three 
different sites of the samples. 
 
  




3.1 Characterization of the SCAD assay 
In order to discover novel anti-fibrotic agents and to explore scarring mechanisms, we 
took advantage of the SCAD assay where uniform scars developed ex vivo. The SCAD 
tissues provided clear morphologic, histologic, and in silico criteria to measure and 
compare scar severity outcomes. Brightfield whole-mount images showed that the 
original SCAD tissue evolved from a flat skin piece into a contracted curved column 
after 5 days of culture. Trichrome staining of the corresponding samples revealed that 
there was an increased ECM accumulation in the scarring area of Day 5 SCAD (Figure 
9a). SCADs developing scars underwent skin contraction, bending the skin towards the 
center of the scar. To test whether the newly formed boarder had re-epithelialized, 
SCAD cryo-sections were stained with cytokeratin 14 (CK14). The 
immunohistochemical staining depicted a clearly distinguished re-epithelialization 
that covered the whole SCAD tissue. Re-epithelialization originated from the skin 
borders and helped to easily visualize and quantify the scar contours within the skin 
explant (Figure 9b). SCAD samples also showed clear histological characterizations 
including fibroblasts that concentrated at skin centers, cross-linked connective tissue 
lattices that bridged between skin folds (Figure 9a and Figure 9b). 
Immunohistochemistry of fibrillar matrix proteins revealed abundant fibronectin and 
little collagen I aligned within ex situ scars (Figure 10). CD26 staining confirmed that 
most of the cells that aggregated at the scar tip are pro-scarring fibroblasts (Figure 9b 
and Figure 10).  
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Figure 9. Histological characteristics of Day 5 SCADs. (a) Trichrome staining of the scar area in SCAD. Scarring area 
was encompassed by a newly formed cell layer (dark red) and inside the layer there were numerous aggregated 
cells (black nuclei, light red cytoplasm) and cross-linked ECM (blue). (b) Immunohistochemistry staining 
demonstrated that the aggregated cells were CD26 positive and the new layer that wrapped the scar was CK14 
positive, implying that activated fibroblasts were gathering, and re-epithelialization occurred. Scale bar: (a), 50 µm; 
(b), 100 µm. 
Figure 10. Immunohistochemistry staining of CD26 and ECM proteins. (a) showed CD26 and fibronectin (FN) 
staining in Day 5 SCAD. (c) showed CD26 and Col I staining in Day5 SCAD. (b) and (d) showed high magnification 














a b CD26 CK14 
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3.2 Primary screening of 1280 chemicals with the SCAD assay  
Aiming to discover biological processes that underpin the fascia’s wound response 
(fascia tissue culminated in SCAD scar), which could potentially open the door towards 
clinical interventional routes, we applied the whole skin SCAD assay in a high-
throughput screening system (Figure 11). Our initial phenotypic screening of 1280 
small molecules (n = 2, each treatment was repeated with 2 independent SCADs) 
identified 122 chemical hits (9.3 % hit) that were selected mainly in the light of clear 
differences in scar severity, showing either increased scarring or a decreased scarring 
or a complete absence of scars. These 120 chemicals were then manually subjected to 
individual chemical screening in order to further corroborate phenotypic changes (n = 
4, each treatment was repeated with 2 independent SCADs). Finally, 26 top chemicals 
that showed consistent scarring phenotypes were selected for further evaluation. 
Overall, we have phenotypically screened more than 3,000 individual SCAD samples 
for clear histological signs of the scarring response. Some chemically treated samples 
showed exuberant scars that extended beyond the centre of the skin explant, some 
showed severe scars with strong contraction forming at closed tissue cylinders. Other 
chemically-treated samples that exhibited dramatically decreased scarring did not 
bend the tissue and the tissue itself was as flat as on Day 0 after five days’ culture 
(Figure 12 left panel). The more severe the scars were, the stronger the contraction 
around the epidermal rims of the skin explant developed (Figure 12 left panel).  
Figure 11. Scheme illustration of the screening process. 
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Our morphological criteria were coupled with a histological analysis of all samples (n= 
4). Here, the severity of scars was further subdivided based on overall scar size, scar 
dimension, and extent of connective tissue formation and organization (Figure 12 
middle panel). A clear range of phenotypes was observed from scarless samples 
marked by negligible or non-existent scars with loose and thin-linked reticular ECM to 
scars that emerged but had drastically different lattice organisation from normal scars, 
with porous and abnormally thickened ECM fibres. More severe scars also emerged 
with dense foci and ECM that extended beyond the borders of the original tissue. Even 
more severe scars exhibited dense cell foci at scar centres with ECM that overtook 
most of the skin explant (Figure 12 middle panel). 
Next, we employed fractal analysis to further classify the severity of scars based on 
values of DF and Lac of the ECM lattice organisation from individual histologic images. 
The DF value reveals changes in detail with different scaling and provides a way to 
measure the complexity of irregular, non-Euclidean shapes. Box counting is the most 
popular way to measure fractal dimension. In brief, variant size (ε) of the box is used 
to cover the whole object and the number of boxes (N) needed to cover the whole 
object is counted. DF is estimated as the slope of the regression line in log N plotted 
against log ε. The less the DF value is, the less complex the tissue texture is. Lacunarity 
refers to the porosity of objects in morphology. The higher the value is, the more 
porous and heterogenous the texture is. Fractal dimension supplemented with 
lacunarity analysis characterized the architecture patterns of the ECM fibres with 
selected phenotypes in the treatments.  
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Figure 12. Brightfield phenotypes and histological analysis of the 26 selected chemicals and DMSO control. The 
images were ordered from top to bottom in accordance with scar severity from less scarring to exaggerated 
scarring. Trend of fractal dimension and lacunarity changes was shown on the right. The brightfield whole mount 
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Quantification of the overall scar severity indicated that out of the 26 phenotypes, 16 
samples (61.5 %) showed reduced severity of lattice organisation, whereas 10 samples 
(38.5 %) showed more severe scar phenotypes, compared to the control SCAD (Figure 
12). From the most anti-scarring chemicals to the most pro-scarring chemicals DF 
values increased and Lac values decreased, suggesting that heavy scarring is of low 
porosity and highly complex texture while light scarring is less complex and more 
porous (Figure 13). Thus, our combined SCAD/small molecule screening approach has 
identified a range of scar severities, all of which were classified into 26 distinct 
morpho-histologic phenotypes. Intriguingly, in depth analysis of the therapeutic 
classes of the individual compounds showed that 6 of the 16 compounds with anti-
scarring response are anti-fungal or anti-bacterial, 4 are anti-inflammatory and 2 are 
anthelmintic. The other 4 anti-scarring compounds were antilipemic, analeptic, 
bronchodilatatoric and analgesic. In contrast the 10 pro-scarring compounds showed 
a variety range of  treatment functions, including anti-bacterial, anti-inflammatory, 
bronchodilatatoric, antiosteoporetic and anthelmintic. Furthermore, contrastant, 
vasodilators, vasoconstrictors, analgesics, and antihypertensive agents were also 
included in this group (Table 5). 
Figure 13. Fractal dimension and lacunarity analysis of 26 selected compounds from Figure 12 showed the trend 
that anti-scarring chemicals were of low DF values and high Lac values, whereas pro-scarring chemicals exhibited 
the opposite performance of DF values and lacunarity values, compared to the control (Ctrl) SCAD. 
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Table 5. Twenty-six hit chemicals screened from PCL 
* “–” represents an effect of decreasing scarring; “+” represents an effect of increasing scarring. The more symbols there are, the stronger effect the chemical showed.  
  
  III. Results 
33 
 
3.3 Development of dermis and fascia explant in suspension assay 
We have recently shown that the superficial fascia is a cell repository for wound 
myofibroblasts and scar tissue [96]. In order to characterize the effects and phenotypic 
responses of the chemicals to fascia directly, we zoomed in on the fascia tissue itself. 
We first established a whole fascia explant suspension assay in order to study the 
fibroblast-centric response to wounds. And we cultured the  corresponding dermis 
tissue by the same approach. After 6 days of culture, whole fascia explants in 
suspension underwent a gradual process of contraction and scarring until forming an 
opaque and dense aggregate of scar tissue, whereas dermis tissue didn’t bend itself 
like in the SCAD culture and displayed a whole-mount morphology as Day 0 SCAD 
(Figure 14). Masson’s trichrome staining confirmed that dermis explants didn’t curve 
and produced almost no ECM, whereas fascia explants formed similar ECM lattice as 
in the SCAD.  
Figure 14. Trichrome staining of dermis and fascia explants cultured in suspension assay. (a) and (b) are 
independent samples showing that after 6 days’ culture dermis tissue didn’t form scarring tissue (upper panel). (c) 
and (d) showed two independent fascia tissues that displayed a fibrotic characteristic like scarring area in SCAD 
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3.4 Characterization of fascia invasion assay  
To look more closely at the dynamics of the fibrotic cells and map the overall cell 
trajectory of fascia EPFs during the scarring process, we crossed our fibroblast lineage-
specific promoter Engrail1 mice to a nuclear mCherry reporter line and imaged fascia 
explants from the offspring. We obtained fascia explants from back skin of En1cre; 
R26mCherry and embedded tissue samples in Matrigel to form a 3D environment. En1- 
positive cells were labelled as mCherry positive cells. In order to understand the 
mechanism underlying the dynamic changes of fascia migration, we took live imaging 
of three different time points. We noticed that cells stayed still on the day the tissue 
was embedded in gel. After one day’s equilibrium, cells adapted themselves to the 
surrounding microenvironment and became activated, as they began to move around 
inside the tissue or escaped from the original tissue (Video 1, Figure 15). Live imaging 
recorded that cells irregularly migrated in all directions at early stage of culture, 
namely from D1 to D2. After one cell run away from the living tissue, they either went 
forward alone or made connections with other cells to assist them in emigration, 
forming sprouts from the original tissue. Cell tracking also demonstrated the random 
movement of activated EPF at early migration stage (Figure 15 c).  
Figure 15. Snapshots and cell tracking of a live imaging recording migration of En1cre; R26mCherry fascia explant from 
D1 to D2. (a) and (b) showed starting point and end point of video. (c) showed automatic tracking of cell migration 
a                                                       b                                                        c       
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routines, each line is a migrating trajectory for one single cell that developed from blue to orange chronologically. 
Scale bar, 100 µm. 
From D2 to D5 an increased number of EPFs were observed migrating out the 
boundary of original tissue. These activated cells showed continuous forward and 
backward movement (Video 2). They sprouted outside the tissue, sensed the 
surrounding milieu, and contacted the nearby cells by elongating cell body and 
producing protrusions. Finally, they found their companions when the protrusion of 
two cells touched each other. And then more and more cells were connected forming 
a network that enveloped the initial tissue. Cells within this envelop continued to 
move, and finally aggregated and formed cell clusters (Figure 16). This kind of 
movement produced a constricting power that contracted the whole tissue. 
Figure 16. Snapshots of a live imaging recording migration of En1cre; R26mCherry fascia explant from D2 to D5. (a) 
showed the starting point of the video when not many cells migrated outside the tissue. (b) showed the middle 
point of the video when more cells escaped from the tissue and formed a network. (c) showed the end point of the 
video when cell clusters formed at last. Dashed lines depicted the boundary of the original tissue. (d) showed 
automatic tracking of cell migration routines, each line is a migrating trajectory for one single cell that developed 
from blue to orange chronologically. Scale bar, 100 µm. 
This tissue self-contraction was further confirmed by the contractile behavior of a 
small cluster of cells escaped from the initial tissue. The escaped cells were arranged 
a                                                                         b           
c                                                                         d           
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like a horizontal “L” at the beginning, but cells in the clusters continued to stretch their 
protrusions to sense the neighbouring environment. At last, two cells at separate ends 
communicated successfully and connected to each other. The size of the original 
tissue simultaneously slowly narrowed down along with the cell-to-cell connection 
(Video 3, Figure 17a and 17b). Analysis of the cell migrating trajectories by cell tracking 
showed that all the cells were heading to the center of the cluster, which supported 
the observation of self-contraction (Figure 17c).  
Figure 17. Snapshots of a live imaging recording migration of En1cre; R26mCherry fascia explant from D7 to D9. (a) 
showed the starting point of the video. (b) showed the end point of the video when the cell clusters contracted. (c) 
showed automatic tracking of cell migration routines. Each line is a migrating trajectory for one single cell that 
developed from blue to orange chronologically. Scale bar, 100 µm.  
In order to investigate in high detail how cell-to-cell connection occurs during 
migration, we took several live imaging videos using fascia tissues from En1cre; R26mTmG 
double transgenic mice, in which En1-positive fibroblastic lineage cells were identified 
as GFP positive. We found that the EPFs possessed a flexible morphology during 
c             
a                                                                         b           
c 
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migration. The cells were equipped with many protrusions which facilitated them to 
alternate their shape for migration. These protrusions not only functioned as 
pseudopodium, but also acted as sensors to detect the surrounding environment 
(Video 4). Once the protrusion detected a protrusion from another cell, the two cells 
advanced towards each other and formed cell-to-cell connection (Figure 18). The 
countless fibroblasts were then interconnected into a web and contacted the original 
tissue with cells lined outwards the original borders of the tissue, showing reticulating 
behavior reminiscent of endothelial cells (Video 4).  
 
Figure 18. Chronological snapshots from a live imaging recording migration of En1cre; R26mTmG fascia explant 
recording EPF making connections with nearby cells (a, b, c, d, e, f). Scale bar, 50 µm.  
Tracking the tissue size and how aggressive EPFs invaded the surrounding gel every 
day, we found that the invasion speed accelerated from day 2 onwards (Figure 19a, 
Figure 20). In addition, the original size of the tissue became smaller and smaller, 
meaning that the tissue continued contracting (Figure 19b). Cell clustering formation 
was further confirmed by a live imaging recording cell migration of En1cre; R26mTmG 
fascia explant (Video 5). Fluorescent signal analysis of the first screenshot and the last 
one of video 5 showed that after 48 hours, there were some sites that showed much 
stronger signal than start point, suggesting that in these areas there were cell 
clustering formation during cell migration (Figure 21).   
a                                                   b                                                  c 
d                                                  e                                                 f 




Figure 19. Dynamic changes of invasion index (a) and contraction index (b) of fascia explant in Matrigel. 
Figure 20. En1cre; R26mTmG fascia explant cultured in 3D Matrigel from D0 to D4. Scale bar, 100 µm. 
Figure 21. Clustering analysis of EPF migration. (a) and (b) showed snapshots of start point and end point from a 
live imaging recording EPFs migration of En1cre; R26mTmG fascia explant from D2 to D5. (c) and (d) compared 
fluorescence signal from individual grids at the two time points. Higher fluorescence means more cells at one site. 
The stronger fluorescence at some sites than other areas showed that EPFs formed stronger cell clustering during 
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The proliferation marker ki67 staining showed that cells stayed silent during the first 
two days and began to proliferate on Day 2 and afterwards continued proliferating 
until Day 4 when samples were collected. Both escaped cells and cells trapped in the 
original tissue kept proliferating (Figure 22).  
Figure 22. Ki67 staining of En1cre; R26mTmG fascia explants from D0 to D4. Scale bar, 100 µm. 
3.5 Secondary screening- retest chemical hits in fascia invasion assay 
The fascia invasion assay permitted an unparalleled view of the effect of small 
molecules on the scarring process. Having discovered classes of chemicals with anti- 
and pro-scarring responses, we therefore re-tested the 26 chemicals in the fascia 
invasion assay. Calculation of the invasion index demonstrated that the responses of 
these compounds to fascia tissue were consistent with those in SCAD assays (Figure 
23). Chemicals that displayed an anti-scarring activity showed a weakened migration 
and invasion ability, while those with pro-scarring effects provoked a more aggressive 
invasion capacity than DMSO control (Figure 23). By imaging treated tissues at single 
cell level we found that the types and numbers of protrusions produced by EPFs were 
proportional to their invasion ability. In the DMSO control samples, EPFs possessed a 
morphology of elongated spindle shape with long, thick, and bifurcated protrusions. 
In pro-scarring samples, EPFs not only retained long protrusions, but also with more 
bifurcations in protrusions, which was speculated to increase their invasion ability. 
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However, cell morphology of EPFs changed significantly in anti-scarring samples.  EPFs 
in these samples didn’t retain stretched thick protrusions but displayed a damaged 
ability to generate normal protrusions. For example, cells in itraconazole (1139) 
treated samples showed round shaped with just one single protrusion (Figure 24). We 
suspect that the thick and stretched type of protrusion may be related to the 
migration ability of the cell.  
Figure 23. Invasion index of 26 hit chemicals. Red dashed line indicated the invasion level of DMSO control samples. 
From the invasion index analysis combined with the morphological changes of EPF at 
single cell level, we chose three top chemicals to further study the mechanism of their 
anti-scarring effects- itraconazole (1139), Fenbendazole (210) and fluvastatin sodium 
salt (859) (fluvastatin is abbreviated for fluvastatin sodium salt afterwards). However, 
since there was massive cell death after treatment with Fenbendazole, we studied 
only the other two chemicals. Compared to the DMSO control, itraconazole and 
fluvastatin significantly perturbed the connectivity, organization of fascia EPFs and the 
collective migration (Figure 25a). Looking more detailed into the cell-to-cell 
connection we found that with itraconazole treatment cells were mostly individually 
distributed after migration from the original tissue. There was almost no connection 
between migrated cells and the original tissue and also few connections among 
migrated cells. With fluvastatin treatment, the connection between EPFs and tissue 
was not destroyed but damaged to some extent. Migrated cells still connected with 
their nearby counterparts, but the invasion ability was inhibited. High-magnification 
images showed that EPFs in fluvastatin treated fascia tissue EPFs possessed curved but 
not stretched protrusions, which may be the reason of the impaired invasion ability 
(Figure 25b).   
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Figure 24. Morphological changes of EPFs with treatments of 26 chemicals and DMSO control at single cell level. 
Scale bar, 10 µm (n = 3). 
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Figure 25. Multiphoton images of En1cre; R26mTmG fascia explant treated with DMSO, fluvastatin and itraconazole. 
(a) showed how far EPFs migrated outside the tissue. (b) showed morphological changes of corresponding 
treatment with higher magnification. Scale bar: (a), 100 µm; (b), 50 µm. 
3.6 Focal adhesion kinase (FAK) is unrelated to the inhibition of fascia migration 
FAK pathway is an important pathway in a diverse array of metastasis processes, such 
as cell adhesion, migration, and cell invasion [113]. As a key component in the FAK 
pathway, FAK protein has been previously reported to be required for the adhesion 
and migration of various cell types. Inhibition of FAK by small molecular, 1,2,4,5-
Benzenetetramine tetrahydrochloride (Y15), dramatically decreased the migration 
of vascular endothelial cells and human hepatoblastoma cells in a dose-dependent 
way [114]. FAK also mediates fibroblast migration and blocking FAK activation resulted 
in decreased migration ability of lung fibroblasts after bleomycin treatment [115].  
However, immunohistochemistry staining of FAK in our fascia samples showed that 
there was no difference of FAK expression among DMSO control, itraconazole and 
a 
b 
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fluvastatin treatments (Figure 26). In order to further investigate whether the FAK 
pathway was involved in the inhibition of fascia migration, we tested the expression 
of paxillin in treated samples and DMSO control. Paxillin is another important focal 
adhesion protein in the FAK downstream pathway and has been proven to be 
indispensable for directional migration of fibroblasts [116]. However, 3D staining of 
paxillin demonstrated no significant changes of expression in both itraconazole and 
fluvastatin treated tissues and the DMSO control group (Figure 27). These results 
suggested that FAK pathway may not be involved in the inhibition of fascia fibroblast 
migration by itraconazole and fluvastatin.  
Figure 26. Immunohistochemistry staining of FAK in En1cre; R26mTmG fascia explants treated with DMSO, fluvastatin 
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Figure 27. Immunohistochemistry staining of paxillin in En1cre; R26mTmG fascia explants treated with DMSO, 
fluvastatin and itraconazole. Scale bar, 50 µm.  
3.7 Microtubule organization is related to the inhibition of fascia cell migration 
Inspired by the morphological changes of EPFs, we detected alterations of 
microtubule and filamentous actin (F-actin) orientation caused by treatment of DMSO, 
fluvastatin and itraconazole in the FF95 fibroblast cell line. Immunostaining of tubulin 
and phalloidin showed that addition of DMSO resulted in a spindle-shaped, elongated 
fibroblast morphology, whereas fluvastatin treatment led to more elongated cell 
shape and itraconazole treatment resulted in polygonal, spread appearance (Figure 
28). The results were consistent with the single cell images from En1cre; R26mTmG fascia, 
indicating that the alterations in morphological structure were involved in the 
inhibitory effect of EPF migration induced by itraconazole and fluvastatin.  
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Figure 28. Immunocytochemistry staining of phalloidin, tubulin and ECM (Col I, Col III, Fibronectin) in FF95 cells 
treated with DMSO, fluvastatin, itraconazole. Scale bar, 50 µm. 
3.8 Hedgehog pathway is involved in the inhibition of fascia cell migration   
The hedgehog pathway is an important signalling pathway in embryonic development 
and dysregulation of the pathway may lead to fibrosis of several organs. Targeting the 
hedgehog pathway was reported to be a therapeutic strategy to inhibit fibrosis [117]. 
Glioma-associated oncogene homolog 1 (Gli1) is a key transcriptional factor that 
carries signal to nucleus and initiates expression of target genes in hedgehog pathway 
[118]. Overexpression of Gli1 protein has been found in various kinds of carcinomas 
including glioblastomas, osteosarcoma as well as basal cell carcinoma in skin [119-121]. 
Here we found that itraconazole and fluvastatin performed their anti-scarring 
functions via the hedgehog pathway by decreasing Gli1 protein expression (Figure 29).  
Itraconazole is a broad-spectrum anti-fungal drug used in adults. It has been approved 
for medical use in 1992 and is one of the most widely used medicine in basic health 
system. Recently several clinical studies have reported anti-neoplastic functions of 
itraconazole, including in the treatment of acute lymphoblastic leukaemia, refractory 
ovarian cancer, pancreatic and biliary tract cancer [122- 124]. Further investigation of 
the anti-cancer effect indicated that the hedgehog pathway was involved in the anti-
tumour effect. It has been proven that itraconazole inhibited the hedgehog pathway 
by directly acting on Smoothened (SMO), a key element of the pathway that is located 
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in the cell membrane. Specifically, itraconazole prohibits SMO to move from cell 
membrane to primary cilium and thus prevents suppressor of fused protein (Sufu) to 
release Gli activator to the cell nucleus and finally inhibiting the pathway [125]. 
Immunohistochemical staining of Gli1 showed that there was only a low level of Gli1 
expression in itraconazole treated samples (Figure 29). Besides, EPFs were not 
activated into myofibroblasts as αSMA expression was trapped in the nucleus but not 
in cytoplasm (Figure 30). The suppression of αSMA expression in itraconazole treated 
fascia agreed with the previous study that itraconazole can inhibit myofibroblast 
differentiation [126]. 
Figure 29. Gli1 staining of En1cre; R26mTmG fascia explants treated with DMSO and drug treatment implied that 
fluvastatin and itraconazole inhibited the hedgehog pathway by decreasing the expression level of Gli1. Scale bar, 
50 µm. 
Fluvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
reductase, which is a rate-limiting enzyme in cholesterol synthesis. It has been 
reported that cholesterol directly binds to SMO and activates the hedgehog pathway 
[127, 128]. The migrating repression effect of fluvastatin may function through 
inhibiting SMO activation. Immunohistochemistry in fluvastatin-treated samples 
demonstrated weakly expressed Gli1 protein in EPFs (Figure 29). However, intact cell-
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to-cell connection and network formation still occurred, which may be because the 
cholesterol synthesis was not totally blocked. In addition, EPFs in fluvastatin-treated 
fascia samples can still be activated into myofibroblast, as expression of αSMA was 
similar between DMSO control and fluvastatin sample, which explained the remaining 
cell-to-cell connection of escaped cells with fluvastatin treatment (Figure 30).   
Figure 30. αSMA staining of En1cre; R26mTmG fascia explants treated with DMSO and drug treatment implied that 
itraconazole inhibited myofibroblast differentiation whereas fluvastatin had no effect in myofibroblast 
differentiation. Scale bar, 50 µm. 
The hedgehog pathway was also reported to induce proliferation and to depress 
apoptosis. Ki67 and caspase 3 staining showed that cell proliferation activity of both 
itraconazole and fluvastatin treated samples decreased (Figure 31), whereas cell 
death increased (Figure 32). In addition, ECM expression was decreased by both 
itraconazole and fluvastatin treatments when examined in FF95 fibroblasts (Figure 28).  
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Figure 31. Ki67 staining of En1cre; R26mTmG fascia explants treated with DMSO, fluvastatin and itraconazole 
suggested an inhibitory effect in cell proliferation by fluvastatin and itraconazole treatments. Scale bar, 100 µm. 
Figure 32. Caspase3 staining of En1cre; R26mTmG fascia explants treated with DMSO, fluvastatin and itraconazole 
suggested a promoting effect in cell death by fluvastatin and itraconazole treatments. Scale bar, 50 µm. 
  




4.1 3D culture in Matrigel 
As a replacement for animal experiments, standard 2D cell culture has been a widely 
used tool in modern biology that promoted our knowledge in fundamental biology, 
disease pathology, drug reaction and so on [129]. However, the monolayer cell culture 
on a rigid glass or plastic container can’t represent the natural 3D morphology of cells 
due to the absence of a proper physiological microenvironment [130]. These 
limitations have led to growing efforts to develop 3D culture models. Compared to 2D 
cell culture, 3D culture systems provide scaffolds that mimic the natural in vivo 
conditions for cells to attach. Thus, the cells exhibit growth properties more similar to 
those found under physiological conditions. Among the various 3D scaffolds available 
in the market, Matrigel is the most widely utilised [131, 132]. Matrigel is a gelatinous 
protein mixture extracted from murine Engelbreth-Holm-Swarm (EHS) sarcoma cells. 
It is composed of rich matrix proteins including laminin, collagen IV, Nidogen/entactin 
and heparan sulphate glycoprotein, as well as a variety of growth factors [133]. 
Matrigel has been applied in various ex vivo assays such as tube formation assay, cell 
invasion assay and 3D spheroid culture [131].  
It has been reported that many cell types would develop into a tissue-specific 
architecture when cultured under 3D conditions with basement membrane matrix 
[131, 134]. A well-known example is the tube formation assay that mimics the 
angiogenesis process in vivo. When placed in Matrigel, endothelial cells will migrate 
towards each other forming branching structures and finally generate tubes and 
lumens [135, 136]. Another example is the invasion assay to investigate the invasive 
capabilities of tumour cells [137, 138]. To our surprise, fascia explants cultured in 
Matrigel displayed not only characteristics of sprouting and branching resembling 
endothelial cells but also invasion ability resembling tumour cells. Live imaging that 
recorded neonatal fascia explant from En1cre; R26mTmG double transgenic mice showed 
EPFs migrating outside the original tissue and invading the Matrigel. Besides, escaped 
EPFs on the one side dragged neighbouring cells outside the tissue, on the other side 
extended the cell body by producing protrusions. These protrusions detected the 
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surroundings in search for their equivalents. Once protrusions from nearby cells 
contacted, the two cells were connected and then more cells interacted forming a 
capillary-like structure. Finally, a big network with numerous cell clusters was 
constructed, enveloping the whole tissue. In addition, the formation of a cell network 
structure outside fascia tissue simultaneously generated a contractile force that 
tightened the tissue itself, which has not been observed in the tube formation assay.  
Invasiveness that is featured by cancer cells to enhance metastasis is another property 
of fascia fibroblast. It has been reported that when breast tumour cells MCF7S1 were 
co-cultured with mammary fibroblast in Matrigel, the expression of fibroblast specific 
protein 1 (FSP1) was increased in fibroblasts, which led to an enhanced level of MMP2 
secretion and tumour cell invasion [139]. Interestingly, a study comparing the activity 
of the HT1080 fibrosarcoma cell line and normal skin fibroblasts showed that HT1080 
cells in Matrigel possessed a strong migration and proliferation ability. The 
fibrosarcoma cells rapidly invaded the gel and formed capillary-like structure imitating 
endothelial cells, whereas normal fibroblast showed poor migration and invasion 
capability [140]. Here we demonstrate that fascia fibroblasts are featured with 
capacities of aggressive migration and tubule formation that are exhibited by tumour 
cells and endothelial cells. To the best of our knowledge, this is the first study that 
explored the characterization and dynamic alterations of fascia fibroblasts in a 3D 
culture system, at both tissue level and single cell level. 
4.2 Fluvastatin and itraconazole for the treatment of fibrosis 
Fluvastatin is a member of the statin family that functions as a competitive inhibitor 
of HMG-CoA reductase. HMG-CoA reductase is a rate-limiting enzyme in the 
mevalonate pathway to convert HMG-CoA into mevalonate [141]. The restrained 
generation of mevalonate subsequently decreases the production of the downstream 
molecules like isopentenyl pyrophosphate (IPP), geranyl pyrophosphate (GPP) and 
farnesyl pyrophosphate (FPP), and at last lowers the biosynthesis level of cholesterol. 
In this respect, statins are a widely used lipid-lowering medication in medicine, 
especially in the treatment of cardiovascular diseases [142]. Except for the classic 
cholesterol-lowering treatment, statins have also been applied to treat various skin 
disorders, as the skin is an important organ that deposits cholesterol. It has been 
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reported that daily intraperitoneal (IP) injection of 5mg/kg of Simvastatin alleviated 
the weakened wound healing in female diabetic mice (db+/db+) by enhancing 
expression of VEGF [143]. Besides, Simvastatin can also reduce immune cell infiltration 
in infected wounds and improve the healing process [144]. In addition, statins have an 
anti-fibrotic effect in a variety of fibrosis models such as lung, heart, tenon and 
systemic sclerosis by moderating TGF-β signalling pathway [145-148]. In vitro evidence 
proved that the anti-fibrosis effect of statins was attributed to the down regulation of 
CTGF, a pro-fibrotic growth factor that is provoked by TGF-β [149]. TGF-β plays a key 
role in tissue remodeling, and especially advance the progression towards fibrosis. The 
downstream regulation of TGF-β signalling is usually moderated by Smad protein. 
However, gene expression assays showed that the expression of CTGF was 
independent of Smad protein. CTGF seemed to be a potential candidate to specifically 
arrests the pro-scarring effect of TGF-β but reserves the other biological activities of 
TGF-β [150]. In skin fibrosis statins also demonstrated an inhibitory effect of 
pathological scar formation. In a hypertrophic scar model of rabbit ear, low dose local 
injection (40 µM) of Simvastatin, Lovastatin and Pravastatin dramatically reduced the 
scar elevation index by hampering CTGF levels [151].  In our study, we showed that 
fluvastatin sodium salt, a chemically synthesized statin, significantly hampered the 
migration and invasion ability of fascia fibroblasts. However, whether fluvastatin 
treatment can inhibit the expression of CTGF needs to be confirmed. 
Itraconazole is a wide-spectrum anti-fungal medication to treat various infections 
including pulmonary aspergillosis, blastomycosis, as well as dermatophytosis [152- 
154]. The drug is orally applicable, well-tolerated, and can be used to treat fungal 
infection of any part of the body that suffers from a fungal infection [155, 156]. Except 
the anti-infection activity, itraconazole has recently been found to be able to exhibit 
many other properties. It was reported that itraconazole treatment inhibited the 
migration and tubule formation capability of human umbilical vein endothelial cells 
(HUVEC) in vitro [157]. A screening study identified itraconazole from 210 FDA 
approved drugs to be able to inhibit cell proliferation activity of HUVEC by arresting 
cell cycle at G1 phase and blocking VEGF/ bFGF dependent angiogenesis [158]. In 
addition, a clinical study showed that itraconazole can absolutely resolve pustules on 
  IV. Discussion 
52 
 
the arms of patients with palmoplantar pustulosis [159]. Another screening assay 
identified itraconazole out of about 80,000 small molecules as an effective inhibitor of 
myofibroblast differentiation, which may contribute to new therapeutic strategies to 
treat fibrosis-related diseases [160]. In the respect of skin fibrosis, itraconazole has 
been tested in clinics to treat hypertrophic scars and keloids as well. There was a great 
improvement after two weeks of itraconazole administration [161]. However, as 
itraconazole is an anti-fungal drug, the authors attributed the anti-scarring effect to 
the declined level of fungal infection [161].  
In our study, itraconazole exhibited an anti-scarring effect in the SCAD fibrosis model 
and ameliorated the migration and invasion ability of fibroblasts in the fascia invasion 
assay. In addition, itraconazole damaged the network formation and cell clustering 
activity of fascia fibroblasts in the 3D environment. These results suggest that 
itraconazole is a potential candidate for the prevention and recovery treatment of skin 
scarring. 
4.3 Hedgehog pathway in fibrosis 
The hedgehog signalling pathway is of critical importance in embryonic development, 
organogenesis, and internal organ patterning [162]. In mammals there are three 
different hedgehog pathways due to the different binding ligands- Sonic Hedgehog 
(SHH), Indian Hedgehog (IHH) or Desert Hedgehog (DHH) [163]. Initiation of hedgehog 
pathway is performed by the binding of hedgehog ligand to the 12-pass 
transmembrane receptor patched protein (PTCH). Once HH ligand binds to PTCH, the 
7-pass transmembrane protein SMO is activated and released which leads to SMO 
phosphorylation and accumulation in primary cilium [164]. Phosphorylated SMO 
induces a subsequent signalling cascade by releasing Gli1/2 protein from HH 
suppressor SuFu and kif7 [165]. In the absence of HH ligand, Gli1 protein is 
phosphorylated by protein kinase A (PKA), Glycogen synthase kinase 3β (GSK3β) and 
Casein kinase 1 (CK1) and is processed to bind to transcriptional suppressor or to 
undergo ubiquitination for degradation [166]. In the presence of HH ligand, Gli1 will 
be differently phosphorylated and subsequently translocate to nucleus to activate the 
transcription process, initiating expression of pathway target genes including PTCH, 
Gli1 and Gli2 genes that generate positive feedback to the pathway, and Cyclin D1 
  IV. Discussion 
53 
 
gene that promotes cell proliferation, as well as CCND2 and CCNE1 genes that control 
the cell cycle [167, 168].  
The hedgehog pathway is highly organised and conserved across species. Abnormal 
activation and dysregulation of HH signalling would result in organ hemostasis and 
cancer [169-171]. Recent studies reveal that hedgehog pathway plays an important 
role in multiple organ fibrogenesis and regeneration. SHH overexpression was found 
in human patients with idiopathic pulmonary fibrosis (IPF) and interstitial pneumonias 
[172, 173]. In a bleomycin model that causes acute injury in lung, injection of an SMO 
inhibitor IPI-926 ten days ahead of bleomycin treatment can significantly protect lung 
tissue from fibrosis, as implied by the fast recovery of body weight of the animals and 
decreased mRNA level of Col I and αSMA [174]. Targeting the hedgehog pathway can 
also be a potential treatment for liver fibrosis. In a carbon tetrachloride (CCl4)-induced 
liver fibrosis model, Gant61, a hedgehog inhibitor that is used to target at Gli1 and 
Gli2 proteins, alleviated the fibrotic level of liver and downregulated the expression 
level of SMO, Gli1 and Gli2 [175]. In addition, Gli1 overexpression is also detected in 
systemic sclerosis, renal fibrosis, and biliary fibrosis [176-178]. However, very little is 
known about the role of hedgehog pathway in skin scarring. 
Fluvastatin inhibits the rate-controlling enzyme HMG-CoA reductase in the 
mevalonate pathway and leads to inhibition of cholesterol secretion. Cholesterol is 
the endogenous activator of SMO in the hedgehog pathway and can directly bind to 
SMO to activate it. The hedgehog pathway has been reported to be regulated by 
controlling the access of SMO to cholesterol in vertebrate [179-181]. In our study, 
fluvastatin treated fascia cells exhibited an atypical cell morphology that weakened 
the migration and invasion ability of fascia fibroblasts. By detecting Gli1 expression, 
we suspected that fluvastatin inhibited fascia migration by inhibiting the hedgehog 
pathway through downregulating Gli1 gene.  
Itraconazole can directly bind to SMO and thus hinder its release to initiate the 
following signalling cascade events. Previous studies have shown that itraconazole can 
inhibit cancer progression and cancer cell proliferation, increase apoptosis, and block 
the cell cycle in various carcinomas through inhibiting the hedgehog pathway [182-
184]. Besides, itraconazole was also administered in a murine peritoneal fibrosis 
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model to test the inhibition ability of fibrosis and the underlying mechanism. After 4 
weeks of IP injection, the itraconazole treatment group significantly reduced the 
thickening of the peritoneal wall compared to the control group. At the same time, 
the expression of sonic hedgehog pathway related genes such as SMO, PTCH, SHH and 
Gli1 ligand were decreased in the itraconazole treatment group, suggesting that the 
SHH signalling pathway may be involved in peritoneal fibrosis and blockage of this 
pathway could be an alternative therapeutic choice to treat peritoneal fibrosis [185]. 
To the best of our knowledge, even though itraconazole has been applied to treat 
nonfungal cutaneous disease, but none of the research has focused the mechanism 
on Hedgehog pathway [186]. In our study we confirmed that itraconazole inhibited 
proliferation and migration of fascia fibroblasts, destroyed cell network, and 
promoted apoptosis by downregulating the hedgehog pathway through Gli1 protein. 
  




5.1 Twenty-six hits were screened from PCL with SCAD assay 
From a chemical library containing 1280 agents, we screened 120 potential hits 
showing increased scarring or decreased scarring based on their phenotypic 
performance in SCAD assay. Then we conducted individual screening for these 120 
chemicals and identified 26 top chemicals with consistent phenotypes. Quantification 
of the overall scar severity indicated that out of the 26 phenotypes, 16 chemicals 
(61.5 %) showed reduced severity of lattice organisation, and 10 chemicals (38.5 %) 
showed increased and more dense scarring. Fractal dimension and lacunarity analysis 
revealed that heavy scar tissue is of low porosity and highly complex texture while 
light scarring is more porous and less complicated. 
5.2 Establishment and characterization of a 3D fascia invasion assay  
Build on the fact that fascia is the main contributor of scarring, we established a 3D 
fascia invasion assay. Live imaging at different time points elaborated the dynamic 
process of cell migration and cell-to-cell connection. Fascia cells at first migrated 
randomly outside the original tissue, then migrated cells connected to following cells, 
forming sprouting and branching structure resembling endothelial cells. At last, this 
branching structure integrated into a big network that enfolded the whole tissue and 
contracted it. This is the first report showing the branching and network formation of 
fascia fibroblasts that may give a hint to explain the mechanism underlying fascia’s 
contribution to deep wound and scarring. 
5.3 Two top scarring- inhibiting drugs were identified 
The 26 compounds described in 5.1 were re-tested in the fascia invasion assay. Based 
on the invasion index itraconazole and fluvastatin were identified as the top two anti-
scarring compounds. Single-cell resolution images showed that fascia fibroblasts 
displayed different morphological changes after treatments. Upon itraconazole 
exposure, only a single short protrusion was formed by the cells, whereas with 
fluvastatin treatment, the protrusion showed a wave-pattern. In 
immunohistochemistry, there were no hints pointing to the inhibition of the FAK-
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pathway, suggesting that the FAK-pathway may not play a key role in the anti-scarring 
effect of itraconazole and fluvastatin. In contrast, decreased expression of Gli1 in 
immunohistochemistry suggests that the hedgehog pathway may be involved in the 
scar-inhibiting effects of itraconazole and fluvastatin. This finding implied that 
inhibition of the hedgehog pathway might offer a therapeutic approach to treat 
scarring.  
  




5.1 Sechsundzwanzig Treffer wurden mit einem SCAD-Assay aus PCL gescreent  
In der insgesamt 1280 Substanzen umfassenden chemischen Bibliothek konnten in 
einem ersten Screening 120 potenzielle Treffer ermittelt werden, die im SCAD-Assay 
eine phänotypisch erhöhte Narbenbildung bzw. eine verringerte Narbenbildung 
zeigten. In einem anschließenden individuellen Screening wurden 26 Top- 
Chemikalien mit konsistenten Phänotypen identifiziert. Die Quantifizierung des 
Gesamtschweregrads der Narben ergab, dass von den 26 Phänotypen 16 Chemikalien 
(61,5 %) einen verringerten Schweregrad der Narbenbildung zeigten, während 10 
Chemikalien (38,5 %) eine erhöhte und dichtere Narbenbildung provozierten. Die 
Analyse der fraktalen Dimension und der Lakunenbildung ergab, dass stark 
ausgeprägtes Narbengewebe eine geringe Porosität und eine hochkomplexe Textur aufweist, 
während leichte Narben poröser und weniger komplex sind. 
5.2 Erstellung und Charakterisierung eines 3D-Faszieninvasionsassays 
Aufbauend auf der Tatsache, dass die Faszie sehr stark zur Narbenbildung beiträgt, 
haben wir einen 3D-Faszieninvasionsassay erstellt. Dieser erlaubte im Rahmen von 
Live-Imaging Aufnahmen den dynamischen Prozess der Zellmigration und des Aufbaus 
von Zell-zu-Zell Kontakten darzustellen. Die Faszienzellen zeigten zunächst eine 
zufällige Bewegung aus dem ursprünglichen Gewebeverband heraus und verbanden 
sich dann mit nachfolgenden Zellen, wobei Verzweigungen ausgebildet wurden, die 
Endothelzellen ähnelten. Diese Verästelungen wurden schlussendlich in ein 
Gesamtnetzwerk integriert, welches das gesamte Gewebe umhüllte und zu einer 
Gewebekonstriktion führte.  Dies ist der erste Bericht, der die Verzweigung und 
Netzbildung von Faszien-Fibroblasten beschreibt und damit einen Hinweis auf den 
Beitrag der Faszien an tiefen Wunden und dem Verlauf der Narbenbildung gibt. 
5.2 Zwei Wirkstoffe mit Narben-hemmenden Eigenschaften wurden identifiziert 
Die unter 5.1 beschriebenen 26 Substanzen wurden im Faszieninvasionsassay getestet. 
Aufgrund ihres Invasionsindexes wurden itraconazol und fluvastatin als die beiden 
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Top-Substanzen identifiziert, die einer überschießenden Narbenbildung 
entgegenwirkten. Hochauflösende Einzelzellaufnahmen zeigten unterschiedliche 
morphologische Veränderungen bedingt durch die Behandlung. Unter Itraconazol 
Einfluss bildete sich eine einzelne, kurze Vorwölbung, wohingegen die fluvastatin 
Behandlung wellenartige Zellausläufer bedingt.  In der Immunhistochemie konnten 
keine Hinweise auf die Hemmung des FAK-Pathways gefunden werden, was darauf 
hindeutet, dass der FAK-Pathway möglicherweise keine Schlüsselrolle bei der Anti-
Narben-Wirkung von itraconazol und fluvastatin spielt. Im Gegensatz dazu weist die 
verminderte Expression von Gli1 in der Immunhistochemie darauf hin, dass der 
Hedgehog-Pathway in den Narben-hemmenden Effekt von itraconazol und fluvastatin 
involviert sein könnte. Dieser Befund impliziert, dass die Hemmung des Hedgehog-
Pathway einen therapeutischen Ansatz liefern könnte, um eine Narbenbildung zu 
behandeln. 
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